Navigation Links
Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
Date:5/2/2012

SAN DIEGO, May 2, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's Chief Commercial Officer Scott Byrd will present the company's corporate overview on Tuesday, May 8, 2012 at 4:50pm Eastern Time (1:50pm Pacific Time) during the Deutsche Bank Securities, Inc. 37th Annual Health Care Conference at the Intercontinental Boston Hotel in Boston.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 30 days.

About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.  The current version of Cadence Pharmaceuticals' corporate overview may be viewed on the "Investors" page of www.cadencepharm.com, under "Events and Presentations."  Contacts:

William R. LaRueSVP, CFOCadence Pharmaceuticals, Inc.858-436-1400


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
2. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2011 Financial Results on August 3, 2011
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
5. Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
6. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
7. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
8. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
9. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
10. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
11. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... ... January 13, 2017 , ... FireflySci ... it has found among its diverse customer base. The latest entry in this ... brands electroporators including BTX and Bio-Rad. FireflySci is introducing three distinct varieties including ...
(Date:1/12/2017)... Carolina (PRWEB) , ... January 12, 2017 , ... Each ... the Eureka Index – a process that evaluates the patent estate of a company, ... Immunolight LLC , a biomedical firm leading the way in technologies that transform energy ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... 26-year-old Lisa Rosendahl’s doctors gave her only a few months to live. Now ... combination that has stabilized Rosendahl’s disease and increased both the quantity and quality ...
(Date:1/12/2017)... , January 12, 2017 A new report published by Allied ... - Global Opportunity Analysis and Industry Forecast, 2014-2022," projects that the global in vitro ... growing at a CAGR of 15.07% during the forecast period. ... ... ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 15, 2016 Advancements ... experience, health wellness and wellbeing (HWW), and ... in three new passenger vehicles begin to ... gesture recognition, heart beat monitoring, brain wave ... facial monitoring, and pulse detection. These will ...
(Date:12/8/2016)... Dec. 8, 2016  Singulex, Inc., the leader in ... entered into a license and supply agreement with Thermo ... agreement provides Singulex access to Thermo Scientific BRAHMS PCT ... is used to diagnose systemic bacterial infection and ... to aid in assessing the risk of critically ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... priced an offering of €500.0 million principal amount of its ... amount of its 2.425% senior unsecured notes due 2026. ... occur on December 13, 2016, subject to the satisfaction of customary ... basis. The Company intends to ...
Breaking Biology News(10 mins):